Last 7 days
-7.6%
Last 30 days
-6.3%
Last 90 days
-11.7%
Trailing 12 Months
19.7%
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 38.8% | 39,843 | 28,700 | 18,074 | 12,949 | 10,178 |
Operating Expenses | - | 192,953 | - | - | - | - |
S&GA Expenses | 0.8% | 81,599 | 80,962 | 77,164 | 69,819 | 57,682 |
R&D Expenses | -2.7% | 155,696 | 160,008 | 152,418 | 143,603 | 135,271 |
Interest Expenses | -3.5% | 55.00 | 57.00 | 168 | 440 | 680 |
Net Income | 3.0% | -239,476 | -246,917 | -233,900 | -211,741 | -186,479 |
Net Income Margin | 30.1% | -6.01* | -8.60* | -10.38* | -3.94* | -18.32* |
Free Cahsflow | 9.7% | -120,583 | -133,478 | -113,428 | -75,195 | -198,412 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 14.7% | 701 | 612 | 673 | 734 | 610 |
Current Assets | 18.3% | 570 | 482 | 546 | 619 | 535 |
Cash Equivalents | 21.0% | 550 | 455 | 454 | 508 | 285 |
Net PPE | 2.8% | 88.00 | 86.00 | 82.00 | 71.00 | 65.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -3.6% | 215 | 223 | 235 | 241 | 67.00 |
Current Liabilities | 20.7% | 100 | 83.00 | 97.00 | 86.00 | 47.00 |
Long Term Debt | - | 1.00 | - | - | - | - |
Shareholder's Equity | 25.2% | 486 | 388 | 438 | 494 | 543 |
Retained Earnings | -9.9% | -639 | -582 | -521 | -456 | -400 |
Additional Paid-In Capital | 16.0% | 1,125 | 970 | 959 | 950 | 943 |
Shares Outstanding | 9.7% | 191 | 174 | 173 | 171 | 170 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 16.4% | -83.52 | -99.93 | -78.44 | -50.47 | -158 |
Share Based Compensation | 13.7% | 28.00 | 25.00 | 19.00 | 19.00 | 15.00 |
Cashflow From Investing | 29.7% | 193 | 149 | -97.87 | -109 | -271 |
Cashflow From Financing | 1318.0% | 154 | 11.00 | -2.55 | 458 | 459 |
96.0%
96.0%
83.2%
Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | added | 14.94 | -38,398,200 | 191,369,000 | 0.20% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 9.41 | -26,251 | 101,749 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -67.51 | -59,000 | 18,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -154,415 | 405,585 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 6.08 | -405,000 | 1,345,000 | 0.01% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -52,000 | - | -% |
2023-02-15 | MetLife Investment Management, LLC | unchanged | - | -211,639 | 556,361 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | reduced | -87.93 | -31,433,400 | 3,011,560 | -% |
2023-02-15 | JANE STREET GROUP, LLC | reduced | -21.52 | -158,113 | 208,887 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -24,429 | 64,571 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | lux capital management, llc | 3.3% | 6,004,722 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 5.54% | 10,057,363 | SC 13G | |
Feb 03, 2023 | blackrock inc. | 5.9% | 10,667,624 | SC 13G | |
Jan 24, 2023 | baillie gifford & co | 13.66% | 24,820,850 | SC 13G/A | |
Oct 31, 2022 | mubadala investment co pjsc | 6.3% | 11,291,937 | SC 13D/A | |
Feb 14, 2022 | data collective iv, l.p. | 3.7% | 5,941,120 | SC 13G | |
Feb 14, 2022 | lux capital management, llc | 8.2% | 13,021,519 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.65 -91.31% | 0.69 -90.78% | 0.86 -88.50% | 1.13 -84.89% | 1.67 -77.67% |
Current Inflation | 0.64 -91.44% | 0.68 -90.91% | 0.83 -88.90% | 1.06 -85.83% | 1.53 -79.55% |
Very High Inflation | 0.64 -91.44% | 0.67 -91.04% | 0.80 -89.30% | 0.99 -86.76% | 1.36 -81.82% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 8-K | Current Report | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 4 | Insider Trading | |
Feb 27, 2023 | 10-K | Annual Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-09 | Gibson Christopher | sold | -116,620 | 7.7747 | -15,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -8,086 | 8.0867 | -1,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -573,925 | 8.096 | -70,890 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -32,361 | 8.0904 | -4,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 20,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -161,900 | 8.095 | -20,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 4,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | 232,500 | 2.48 | 93,750 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 1,000 | chief executive officer |
2023-03-08 | Gibson Christopher | gifted | - | - | -10,000 | chief executive officer |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | |||
Revenue | $ 39,843 | $ 10,178 | $ 3,962 |
Operating costs and expenses | |||
Cost of revenue | 48,275 | 0 | 0 |
Research and development | 155,696 | 135,271 | 63,319 |
General and administrative | 81,599 | 57,682 | 25,258 |
Total operating costs and expenses | 285,570 | 192,953 | 88,577 |
Loss from operations | (245,727) | (182,775) | (84,615) |
Other income (loss), net | 6,251 | (3,704) | (2,391) |
Net loss | $ (239,476) | $ (186,479) | $ (87,006) |
Per share data | |||
Net loss per share of Class A and B common stock, basic (in dollars per share) | $ (1.36) | $ (1.49) | $ (3.99) |
Net loss per share of Class A and B common stock, diluted (in dollars per share) | $ (1.36) | $ (1.49) | $ (3.99) |
Weighted-average shares (Class A and B) outstanding, basic (in shares) | 175,537,487 | 125,348,110 | 21,781,386 |
Weighted-average shares (Class A and B) outstanding, diluted (in shares) | 175,537,487 | 125,348,110 | 21,781,386 |
Operating revenue | |||
Revenue | |||
Revenue | $ 39,681 | $ 10,000 | $ 3,413 |
Grant revenue | |||
Revenue | |||
Revenue | $ 162 | $ 178 | $ 549 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 549,912 | $ 285,116 |
Restricted cash | 1,280 | 1,552 |
Accounts receivable | 0 | 34 |
Other receivables | 2,753 | 9,056 |
Investments | 0 | 231,446 |
Other current assets | 15,869 | 7,514 |
Total current assets | 569,814 | 534,718 |
Restricted cash, non-current | 7,920 | 8,681 |
Property and equipment, net | 88,192 | 64,725 |
Operating lease right-of-use assets | 33,255 | 0 |
Intangible assets, net | 1,306 | 1,385 |
Goodwill | 801 | 801 |
Other non-current assets | 0 | 35 |
Total assets | 701,288 | 610,345 |
Current liabilities | ||
Accounts payable | 4,586 | 2,819 |
Accrued expenses and other liabilities | 32,904 | 32,333 |
Unearned revenue | 56,726 | 10,000 |
Notes payable | 97 | 90 |
Operating lease liabilities | 5,952 | 0 |
Lease incentive obligation | 0 | 1,416 |
Total current liabilities | 100,265 | 46,658 |
Deferred rent | 0 | 4,110 |
Unearned revenue, non-current | 70,261 | 6,667 |
Notes payable, non-current | 536 | 633 |
Operating lease liabilities, non-current | 44,420 | 0 |
Lease incentive obligation, non-current | 0 | 9,339 |
Total liabilities | 215,482 | 67,407 |
Commitments and contingencies (Note 9) | ||
Stockholders’ equity | ||
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2022 and December 31, 2021, respectively; 191,022,864 shares (Class A 183,209,655 and Class B 7,813,209) and 170,272,462 (Class A 160,906,245 and Class B 9,366,217) issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 2 | 2 |
Additional paid-in capital | 1,125,360 | 943,142 |
Accumulated deficit | (639,556) | (400,080) |
Accumulated other comprehensive loss | 0 | (126) |
Total stockholders’ equity | 485,806 | 542,938 |
Total liabilities and stockholders’ equity | $ 701,288 | $ 610,345 |